A global perspective of radiation-induced signal transduction pathways in cancer therapeutics

Indian Journal of Experimental Biology

Volumn 42, Issue 12, 2004, Pages 1153-1176

  Gupta, Seema ^a   Ahmed, Mansoor M ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Genes; Inhibitors and therapy; Radiation; Signal transduction pathways

Indexed keywords

CELLS; DRUG PRODUCTS; GENES; IONIZING RADIATION; MOLECULAR BIOLOGY; ONCOLOGY;

APOPTOSIS; SIGNALLING PATHWAYS;

TUMORS;

ANIMAL; APOPTOSIS; BIOLOGICAL MODEL; GENETICS; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY; RADIATION EXPOSURE; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 10344246085     PISSN: 00195189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (332)

1. Haimovitz-Friedman A, Radiation-induced signal transduction and stress response, Radiat Res, 150 (1998) S102.
2. Jonathan E C, Bernhard E J & McKenna W G, How does radiation kill cells? Curr Opin Chem Biol, 3 (1999) 77.
3. Ross G M, Induction of cell death by radiotherapy, Endocr Relat Cancer, 6 (1999) 41.
4. Lin X, Ramamurthi K, Mishima M, Kondo A & Howell S B, p53 interacts with the DNA mismatch repair system to modulate the cytotoxicity & mutagenicity of hydrogen peroxide, Mol Pharmacol, 58 (2000) 1222.
5. Dewey W C, Miller H H & Leeper D B, Chromosomal aberrations and mortality of x-irradiated mammalian cells: Emphasis on repair, Proc Natl Acad Sci U S A, 68 (1971) 667.
6. Steel G G, Recovery kinetics deduced from continuous low dose-rate experiments, Radiother Oncol, 14 (1989) 337.
7. Bedford J S, Sublethal damage, potentially lethal damage, and chromosomal aberrations in mammalian cells exposed to ionizing radiations, Int J Radiat Oncol Biol Phys, 21 (1991) 1457.
8. Nagane M, Huang H J & Cavenee W K, The potential of TRAIL for cancer chemotherapy, Apoptosis, 6 (2001) 191.
9. Wyllie A H, Kerr J F & Currie A R, Cell death: the significance of apoptosis, Int Rev Cytol, 68 (1980) 251.
10. Thornberry N A & Lazebnik Y, Caspases: enemies within, Science, 281 (1998) 1312.
11. Kerr J F, Winterford C M & Harmon B V, Apoptosis. Its significance in cancer and cancer therapy, Cancer, 73 (1994) 2013.
12. Schmitt C A & Lowe S W, Apoptosis and therapy, J Pathol, 187 (1999) 127.
13. Tamm I, Schriever F & Dorken B, Apoptosis: implications of basic research for clinical oncology, Lancet Oncol, 2 (2001) 33.
14. Kerr J F, Wyllie A H & Currie A R, Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics, Br J Cancer, 26 (1972) 239.
15. Reed J C, Mechanisms of apoptosis avoidance in cancer, Curr Opin Oncol, 11 (1999) 68.
16. Earnshaw W C, Martins L M & Kaufmann S H, Mammalian caspases: Structure, activation, substrates, and functions during apoptosis, Annu Rev Biochem, 68 (1999) 383.
17. Green D R & Reed J C, Mitochondria and apoptosis, Science, 281 (1998) 1309.
18. Kaufmann S H, Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note, Cancer Res, 49 (1989) 5870.
19. Bose R, Verheij M, Haimovitz-Friedman A, Scotto K, Fuks Z & Kolesnick R, Ceramide synthase mediates daunorubicin-induced apoptosis: An alternative mechanism for generating death signals, Cell, 82 (1995) 405.
20. Huschtscha L I, Bartier W A, Ross C E & Tattersall M H, Characteristics of cancer cell death after exposure to cytotoxic drugs in vitro, Br J Cancer, 73 (1996) 54.
21. Shinomiya N, Shinomiya M, Wakiyama H, Katsura Y & Rokutanda M, Enhancement of CDDP cytotoxicity by caffeine is characterized by apoptotic cell death, Exp Cell Res, 210 (1994) 236.
22. Walker P R, Smith C, Youdale T, Leblanc J, Whitfield J F & Sikorska M, Topoisomerase II-reactive chemotherapeutic drugs induce apoptosis in thymocytes, Cancer Res, 51 (1991) 1078.
23. Ashkenazi A & Dixit V M, Death receptors: Signaling and modulation, Science, 281 (1998) 1305.
24. Golstein P, Cell death: TRAIL and its receptors, Curr Biol, 7 (1997) R750.
25. Nagata S, Apoptosis by death factor, Cell, 88 (1997) 355.
26. Reed J C, Dysregulation of apoptosis in cancer, J Clin Oncol, 17 (1999) 2941.
27. Weichselbaum R R, Hallahan D, Fuks Z & Kufe D, Radiation induction of immediate early genes: Effectors of the radiation-stress response, Int J Radiat Oncol Biol Phys, 30 (1994) 229.
28. Datta R, Hallahan D E, Kharbanda S M, Rubin E, Sherman M L, Huberman E, Weichselbaum R R & Kufe D W, Involvement of reactive oxygen intermediates in the induction of c-jun gene transcription by ionizing radiation, Biochemistry, 31 (1992) 8300.
29. Sukhatme V P, Early transcriptional events in cell growth: The Egr family, J Am Soc Nephrol, 1 (1990) 859.
30. Mercurio F & Manning A M, NF-kappaB as a primary regulator of the stress response, Oncogene, 18 (1999) 6163.
31. Baldwin A S Jr., The NF-kappa B and I kappa B proteins: New discoveries and insights, Annu Rev Immunol, 14 (1996) 649.
32. Foo S Y & Nolan G P, NF-kappaB to the rescue: RELs, apoptosis and cellular transformation, Trends Genet, 15 (1999) 229.
33. May M J & Ghosh S, Signal transduction through NF-kappa B, Immunol Today, 19 (1998) 80.
34. Das K C & White C W, Activation of NF-kappaB by antineoplastic agents. Role of protein kinase C, J Biol Chem, 272 (1997) 14914.
35. Mohan N & Meltz M L, Induction of nuclear factor kappa B after low-dose ionizing radiation involves a reactive oxygen intermediate signaling pathway, Radiat Res, 140 (1994) 97.
36. Baeuerle P A & Baltimore D, NF-kappa B: Ten years after, Cell, 87 (1996) 13.
37. Chen C, Edelstein L C & Gelinas C, The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L), Mol Cell Biol, 20 (2000) 2687.
38. Zong W X, Edelstein L C, Chen C, Bash J & Gelinas C, The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis, Genes Dev, 13 (1999) 382.
39. Lee H H, Dadgostar H, Cheng Q, Shu J & Cheng G, NF-kappaB-mediated up-regulation of Bcl-x and BfI-1/A1 is required for CD40 survival signaling in B lymphocytes, Proc Natl Acad Sci USA, 96 (1999) 9136.
40. Wang C Y, Guttridge D C, Mayo M W & Baldwin A S Jr., NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis, Mol Cell Biol, 19 (1999) 5923.
41. Levin W J, Casey G, Ramos J C, Arboleda M J, Reissmann P T & Slamon D J, Tumor suppressor and immediate early transcription factor genes in non-small cell lung cancer, Chest, 106 (1994) 372S.
42. Sovak M A, Bellas R E, Kim D W, Zanieski G J, Rogers A E, Traish A M & Sonenshein G E, Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer, J Clin Invest, 100 (1997) 2952.
43. Nakshatri H, Bhat-Nakshatri P, Martin D A, Goulet R J Jr. & Sledge G W Jr., Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth, Mol Cell Biol, 17 (1997) 3629.
44. Devalaraja M N, Wang D Z, Ballard D W & Richmond A, Elevated constitutive IkappaB kinase activity and IkappaB-alpha phosphorylation in Hs294T melanoma cells lead to increased basal MGSA/GRO-alpha transcription, Cancer Res, 59 (1999) 1372.
45. Bours V, Dejardin E, Goujon-Letawe F, Merville M P & Castronovo V, The NF-kappa B transcription factor and cancer: high expression of NF-kappa B- and I kappa B-related proteins in tumor cell lines, Biochem Pharmacol, 47 (1994) 145.
46. Mukhopadhyay T, Roth J A & Maxwell S A, Altered expression of the p50 subunit of the NF-kappa B transcription factor complex in non-small cell lung carcinoma, Oncogene, 11 (1995) 999.
47. Miyashita T & Reed J C, Tumor suppressor p53 is a direct transcriptional activator of the human bax gene, Cell, 80 (1995) 293.
48. Schmidt-Ullrich R K, Dent P, Grant S, Mikkelsen R B & Valerie K, Signal transduction and cellular radiation responses, Radiat Res, 153 (2000) 245.
49. Pouget J P & Mather S J, General aspects of the cellular response to low- and high-LET radiation, Eur J Nucl Med, 28 (2001) 541.
50. Valdes F, Murillo M M, Valverde A M, Herrera B, Sanchez A, Benito M, Fernandez M & Fabregat I, Transforming growth factor-beta activates both pro-apoptotic and survival signals in fetal rat hepatocytes, Exp Cell Res, 292 (2004) 209.
51. Yang Y, Zhao S & Song J, Caspase-dependent apoptosis and -independent poly(ADP-ribose) polymerase cleavage induced by transforming growth factor beta1, Int J Biochem Cell Biol, 36 (2004) 223.
52. Kim S G, Jong H S, Kim T Y, Lee J W, Kim N K, Hong S H & Bang Y J, Transforming growth factor-beta 1 induces apoptosis through Fas ligand-independent activation of the Fas death pathway in human gastric SNU-620 carcinoma cells, Mol Biol Cell, 15 (2004) 420.
53. Evan G I, Wyllie A H, Gilbert C S, Littlewood T D, Land H, Brooks M, Waters C M, Penn L Z & Hancock D C, Induction of apoptosis in fibroblasts by c-myc protein, Cell, 69 (1992) 119.
54. Reed J C, Bcl-2 and the regulation of programmed cell death, J Cell Biol, 124 (1994) 1.
55. Rosen E M, Fan S, Rockwell S & Goldberg I D, The molecular and cellular basis of radiosensitivity: Implications for understanding how normal tissues and tumors respond to therapeutic radiation, Cancer Invest, 17 (1999) 56.
56. Schuster N & Krieglstein K, Mechanisms of TGF-beta-mediated apoptosis, Cell Tissue Res, 307 (2002) 1.
57. Moses H L, Yang E Y & Pietenpol J A, TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights, Cell, 63 (1990) 245.
58. Massague J, Cheifetz S, Boyd F T & Andres J L, TGF-beta receptors and TGF-beta binding proteoglycans: recent progress in identifying their functional properties, Ann N Y Acad Sci, 593 (1990) 59.
59. Suardet L, Li C & Little J B, Radio-induced modulation of transforming growth factor beta1 sensitivity in a p53 wild-type human colorectal-cancer cell line, Int J Cancer, 68 (1996) 126.
60. Kyprianou N & Rock S, Radiation-induced apoptosis of human prostate cancer cells is independent of mutant p53 overexpression, Anticancer Res, 18 (1998) 897.
61. Wang J & Robbins M E, Radiation-induced alteration of rat mesangial cell transforming growth factor-beta and expression of the genes associated with the extracellular matrix, Radiat Res, 146 (1996) 561.
62. Ashley D M, Kong F M, Bigner D D & Hale L P, Endogenous expression of transforming growth factor beta1 inhibits growth and tumorigenicity and enhances Fas-mediated apoptosis in a murine high-grade glioma model, Cancer Res, 58 (1998) 302.
63. Tobin S W, Brown M K, Douville K, Payne D C, Eastman A & Arrick B A, Inhibition of transforming growth factor beta signaling in MCF-7 cells results in resistance to tumor necrosis factor alpha: a role for Bcl-2, Cell Growth Differ, 12 (2001) 109.
64. Shima Y, Nakao K, Nakashima T, Kawakami A, Nakata K, Hamasaki K, Kato Y, Eguchi K & Ishii N, Activation of caspase-8 in transforming growth factor-beta-induced apoptosis of human hepatoma cells, Hepatology, 30 (1999) 1215.
65. Foghi A, Teerds K J, van der Donk H, Moore N C & Dorrington J, Induction of apoptosis in thecal/interstitial cells: action of transforming growth factor (TGF) alpha plus TGF beta on bcl-2 and interleukin-1 beta-converting enzyme, J Endocrinol, 157 (1998) 489.
66. Arsura M, Wu M & Sonenshein G E, TGF beta 1 inhibits NF-kappa B/Rel activity inducing apoptosis of B cells: transcriptional activation of I kappa B alpha, Immunity, 5 (1996) 31.
67. Ten Dijke P, Goumans M J, Itoh F & Itoh S, Regulation of cell proliferation by Smad proteins, J Cell Physiol, 191 (2002) 1.
68. Sun L, Wu G, Willson J K, Zborowska E, Yang J, Rajkarunanayake I, Wang J, Gentry L E, Wang X F & Brattain M G, Expression of transforming growth factor beta type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells, J Biol Chem, 269 (1994) 26449.
69. Kadin M E, Cavaille-Coll M W, Gertz R, Massague J, Cheifetz S & George D, Loss of receptors for transforming growth factor beta in human T-cell malignancies, Proc Natl Acad Sci U S A, 91 (1994) 6002.
70. Park K, Kim S J, Bang Y J, Park J G, Kim N K, Roberts A B & Sporn M B, Genetic changes in the transforming growth factor beta (TGF-beta) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-beta, Proc Natl Acad Sci U S A, 91 (1994) 8772.
71. Antonello D, Moore P S, Zamboni G, Falconi M & Scarpa A, Absence of mutations in the transforming growth factor-beta inducible early gene 1, TIEG1, in pancreatic cancer, Cancer Lett, 183 (2002) 179.
72. Ahmed M M, Alcock R A, Chendil D, Dey S, Das A, Venkatasubbarao K, Mohiuddin M, Sun L, Strodel W E & Freeman J W, Restoration of transforming growth factor-beta signaling enhances radiosensitivity by altering the Bcl-2/Bax ratio in the p53 mutant pancreatic cancer cell line MIA PaCa-2, J Biol Chem, 277 (2002) 2234.
73. Schneider P & Tschopp J, Apoptosis induced by death receptors, Pharm Acta Helv, 74 (2000) 281.
74. Bonavida B, Ng C P, Jazirehi A, Schiller G & Mizutani Y, Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: the trail to non-toxic cancer therapeutics (review), Int J Oncol, 15 (1999) 793.
75. Hsu H, Shu H B, Pan M G & Goeddel D V, TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways, Cell, 84 (1996) 299.
76. Rothe M, Sarma V, Dixit V M & Goeddel D V, TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40, Science, 269 (1995) 1424.
77. Beg A A & Baltimore D, An essential role for NF-kappaB in preventing TNF-alpha-induced cell death, Science, 274 (1996) 782.
78. Adams J M & Cory S, The Bcl-2 protein family: arbiters of cell survival, Science, 281 (1998) 1322.
79. Reed J C, Jurgensmeier J M & Matsuyama S, Bcl-2 family proteins and mitochondria, Biochim Biophys Acta, 1366 (1998) 127.
80. Robertson J D, Orrenius S & Zhivotovsky B, Review: nuclear events in apoptosis, J Struct Biol, 129 (2000) 346.
81. Alnemri E S, Mammalian cell death proteases: a family of highly conserved aspartate specific cysteine proteases, J Cell Biochem, 64 (1997) 33.
82. Chang H Y & Yang X, Proteases for cell suicide: functions and regulation of caspases, Microbiol Mol Biol Rev, 64 (2000) 821.
83. Cohen G M, Caspases: the executioners of apoptosis, Biochem J, 326 (Pt 1) (1997) 1.
84. Verheij M & Bartelink H, Radiation-induced apoptosis, Cell Tissue Res, 301 (2000) 133.
85. Cryns V & Yuan J, Proteases to die for, Genes Dev, 12 (1998) 1551.
86. Kothakota S, Azuma T, Reinhard C, Klippel A, Tang J, Chu K, McGarry T J, Kirschner M W, Koths K, Kwiatkowski D J & Williams L T, Caspase-3-generated fragment of gelsolin: effector of morphological change in apoptosis, Science, 278 (1997) 294.
87. Buendia B, Santa-Maria A & Courvalin J C, Caspase-dependent proteolysis of integral and peripheral proteins of nuclear membranes and nuclear pore complex proteins during apoptosis, J Cell Sci, 112 (Pt 11) (1999) 1743.
88. Rao L, Perez D & White E, Lamin proteolysis facilitates nuclear events during apoptosis, J Cell Biol, 135 (1996) 1441.
89. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli K J, Debatin K M, Krammer P H & Peter M E, Two CD95 (APO-1/Fas) signaling pathways, Embo J, 17 (1998) 1675.
90. Arends M J, Morris R G & Wyllie A H, Apoptosis. The role of the endonuclease, Am J Pathol, 136 (1990) 593.
91. Nagata S, Nagase H, Kawane K, Mukae N & Fukuyama H, Degradation of chromosomal DNA during apoptosis, Cell Death Differ, 10 (2003) 108.
92. Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A & Nagata S, A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD, Nature, 391 (1998) 43.
93. Halenbeck R, MacDonald H, Roulston A, Chen T T, Conroy L & Williams L T, CPAN, a human nuclease regulated by the caspase-sensitive inhibitor DFF45, Curr Biol, 8 (1998) 537.
94. McIlroy D, Tanaka M, Sakahira H, Fukuyama H, Suzuki M, Yamamura K, Ohsawa Y, Uchiyama Y & Nagata S, An auxiliary mode of apoptotic DNA fragmentation provided by phagocytes, Genes Dev, 14 (2000) 549.
95. Hanayama R, Tanaka M, Miwa K, Shinohara A, Iwamatsu A & Nagata S, Identification of a factor that links apoptotic cells to phagocytes, Nature, 417 (2002) 182.
96. Lagarkova M A, Iarovaia O V & Razin S V, Large-scale fragmentation of mammalian DNA in the course of apoptosis proceeds via excision of chromosomal DNA loops and their oligomers, J Biol Chem, 270 (1995) 20239.
97. Oberhammer F, Wilson J W, Dive C, Morris I D, Hickman J A, Wakeling A E, Walker P R & Sikorska M, Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation, Embo J, 12 (1993) 3679.
98. Khodarev N N, Bennett T, Shearing N, Sokolova I, Koudelik J, Walter S, Villalobos M & Vaughan A T, LINE L1 retrotransposable element is targeted during the initial stages of apoptotic DNA fragmentation, J Cell Biochem, 79 (2000) 486.
99. Wyllie A H, Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation, Nature, 284 (1980) 555.
100. Peitsch M C, Polzar B, Stephan H, Crompton T, MacDonald H R, Mannherz H G & Tschopp J, Characterization of the endogenous deoxyribonuclease involved in nuclear DNA degradation during apoptosis (programmed cell death), Embo J, 12 (1993) 371.
101. Barry M A & Eastman A, Identification of deoxyribonuclease II as an endonuclease involved in apoptosis, Arch Biochem Biophys, 300 (1993) 440.
102. Montague J W, Hughes F M, Jr. & Cidlowski J A, Native recombinant cyclophilins A, B, and C degrade DNA independently of peptidylprolyl cis-trans-isomerase activity. Potential roles of cyclophilins in apoptosis, J Biol Chem, 272 (1997) 6677.
103. Shiokawa D, Iwamatsu A & Tanuma S, Purification, characterization, and amino acid sequencing of DNase gamma from rat spleen, Arch Biochem Biophys, 346 (1997) 15.
104. Liu X, Zou H, Slaughter C & Wang X, DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis, Cell, 89 (1997) 175.
105. Li L Y, Luo X & Wang X, Endonuclease G is an apoptotic DNase when released from mitochondria, Nature, 412 (2001) 95.
106. van Loo G, Schotte P, van Gurp M, Demol H, Hoorelbeke B, Gevaert K, Rodriguez I, Ruiz-Carrillo A, Vandekerckhove J, Declercq W, Beyaert R & Vandenabeele P, Endonuclease G: a mitochondrial protein released in apoptosis and involved in caspase-independent DNA degradation, Cell Death Differ, 8 (2001) 1136.
107. Susin S A, Lorenzo H K, Zamzami N, Marzo I, Snow B E, Brothers G M, Mangion J, Jacotot E, Costantini P, Loeffler M, Larochette N, Goodlett D R, Aebersold R, Siderovski D P, Penninger J M & Kroemer G, Molecular characterization of mitochondrial apoptosis-inducing factor, Nature, 397 (1999) 441.
108. Liu X, Li P, Widlak P, Zou H, Luo X, Garrard W T & Wang X, The 40-kDa subunit of DNA fragmentation factor induces DNA fragmentation and chromatin condensation during apoptosis, Proc Natl Acad Sci U S A, 95 (1998) 8461.
109. Mukae N, Enari M, Sakahira H, Fukuda Y, Inazawa J, Toh H & Nagata S, Molecular cloning and characterization of human caspase-activated DNase, Proc Natl Acad Sci U S A, 95 (1998) 9123.
110. Sakahira H, Takemura Y & Nagata S, Enzymatic active site of caspase-activated DNase (CAD) and its inhibition by inhibitor of CAD, Arch Biochem Biophys, 388 (2001) 91.
111. Sakahira H, Enari M & Nagata S, Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis, Nature, 391 (1998) 96.
112. McCarty J S, Toh S Y & Li P, Multiple domains of DFF45 bind synergistically to DFF40: roles of caspase cleavage and sequestration of activator domain of DFF40, Biochem Biophys Res Commun, 264 (1999) 181.
113. McCarty J S, Toh S Y & Li P, Study of DFF45 in its role of chaperone and inhibitor: two independent inhibitory domains of DFF40 nuclease activity, Biochem Biophys Res Commun, 264 (1999) 176.
114. Odaka C & Mizuochi T, Macrophages are involved in DNA degradation of apoptotic cells in murine thymus after administration of hydrocortisone, Cell Death Differ, 9 (2002) 104.
115. Fadok V A, Bratton D L, Frasch S C, Warner M L & Henson P M, The role of phosphatidylserine in recognition of apoptotic cells by phagocytes, Cell Death Differ, 5 (1998) 551.
116. Napirei M, Karsunky H, Zevnik B, Stephan H, Mannherz H G & Moroy T, Features of systemic lupus erythematosus in Dnase1-deficient mice, Nat Genet, 25 (2000) 177.
117. Herskowitz I, Functional inactivation of genes by dominant negative mutations, Nature, 329 (1987) 219.
118. Cameron F H & Jennings P A, Specific gene suppression by engineered ribozymes in monkey cells, Proc Natl Acad Sci U S A, 86 (1989) 9139.
119. Agrawal N, Dasaradhi P V, Mohmmed A, Malhotra P, Bhatnagar R K & Mukherjee S K, RNA interference: biology, mechanism, and applications, Microbiol Mol Biol Rev, 67 (2003) 657.
120. Sioud M, Therapeutic siRNAs, Trends Pharmacol Sci, 25 (2004) 22.
121. Sheard M A, Ionizing radiation as a response-enhancing agent for CD95-mediated apoptosis, Int J Cancer, 96 (2001) 213.
122. Schmidt-Ullrich R K, Valerie K, Fogleman P B & Walters J, Radiation-induced autophosphorylation of epidermal growth factor receptor in human malignant mammary and squamous epithelial cells, Radiat Res, 145 (1996) 81.
123. Schmidt-Ullrich R K, Mikkelsen R B, Dent P, Todd D G, Valerie K, Kavanagh B D, Contessa J N, Rorrer W K & Chen P B, Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation, Oncogene, 15 (1997) 1191.
124. Balaban N, Moni J, Shannon M, Dang L, Murphy E & Goldkorn T, The effect of ionizing radiation on signal transduction: antibodies to EGF receptor sensitize A431 cells to radiation, Biochim Biophys Acta, 1314 (1996) 147.
125. Rosette C & Karin M, Ultraviolet light and osmotic stress: activation of the JNK cascade through multiple growth factor and cytokine receptors, Science, 274 (1996) 1194.
126. Xia Z, Dickens M, Raingeaud J, Davis R J & Greenberg M E, Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis, Science, 270 (1995) 1326.
127. Pap M & Cooper G M, Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-Kinase/Akt cell survival pathway, J Biol Chem, 273 (1998) 19929.
128. Reardon D B, Contessa J N, Mikkelsen R B, Valerie K, Amir C, Dent P & Schmidt-Ullrich R K, Dominant negative EGFR-CD533 and inhibition of MAPK modify JNK1 activation and enhance radiation toxicity of human mammary carcinoma cells, Oncogene, 18 (1999) 4756.
129. Carter S, Auer K L, Reardon D B, Birrer M, Fisher P B, Valerie K, Schmidt-Ullrich R, Mikkelsen R & Dent P, Inhibition of the mitogen activated protein (MAP) kinase cascade potentiates cell killing by low dose ionizing radiation in A431 human squamous carcinoma cells, Oncogene, 16 (1998) 2787.
130. Todd D G, Mikkelsen R B, Rorrer W K, Valerie K & Schmidt-Ullrich R K, Ionizing radiation stimulates existing signal transduction pathways involving the activation of epidermal growth factor receptor and ERBB-3, and changes of intracellular calcium in A431 human squamous carcinoma cells, J Recept Signal Transduct Res, 19 (1999) 885.
131. Kanashiro C A & Khalil R A, Signal transduction by protein kinase C in mammalian cells, Clin Exp Pharmacol Physiol, 25 (1998) 974.
132. Mason C S, Springer C J, Cooper R G, Superti-Furga G, Marshall C J & Marais R, Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation, Embo J, 18 (1999) 2137.
133. Dent P, Jelinek T, Morrison D K, Weber M J & Sturgill T W, Reversal of Raf-1 activation by purified and membrane-associated protein phosphatases, Science, 268 (1995) 1902.
134. Dent P, Reardon D B, Morrison D K & Sturgill T W, Regulation of Raf-1 and Raf-1 mutants by Ras-dependent and Ras-independent mechanisms in vitro, Mol Cell Biol, 15 (1995) 4125.
135. Kobayashi T & Cohen P, Activation of serum- and glucocorticoid- regulated protein kinase by agonists that activate phosphatidylinositide 3-kinase is mediated by 3-phosphoinositide-dependent protein kinase-1 (PDK1) and PDK2, Biochem J, 339 (Pt 2) (1999) 319.
136. Shaw M, Cohen P & Alessi D R, Further evidence that the inhibition of glycogen synthase kinase-3beta by IGF-1 is mediated by PDK1/PKB-induced phosphorylation of Ser-9 and not by dephosphorylation of Tyr-216, FEBS Lett, 416 (1997) 307.
137. Dent P, Jarvis W D, Birrer M J, Fisher P B, Schmidt-Ullrich R K & Grant S, The roles of signaling by the p42/p44 mitogen-activated protein (MAP) kinase pathway; a potential route to radio- and chemo-sensitization of tumor cells resulting in the induction of apoptosis and loss of clonogenicity, Leukemia, 12 (1998) 1843.
138. Abbott D W & Holt J T, Mitogen-activated protein kinase kinase 2 activation is essential for progression through the G2/M checkpoint arrest in cells exposed to ionizing radiation, J Biol Chem, 274 (1999) 2732.
139. Vrana J A, Grant S & Dent P, Inhibition of the MAPK pathway abrogates BCL2-mediated survival of leukemia cells after exposure to low-dose ionizing radiation, Radiat Res, 151 (1999) 559.
140. Bogoyevitch M A, Boehm I, Oakley A, Ketterman A J & Barr R K, Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potential, Biochim Biophys Acta, 1697 (2004) 89.
141. Allen L F, Sebolt-Leopold J & Meyer M B, CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK), Semin Oncol, 30 (2003) 105.
142. Herbst R S & Langer C J, Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers, Semin Oncol, 29 (2002) 27.
143. Lammering G, Hewit T H, Hawkins W T, Contessa J N, Reardon D B, Lin P S, Valerie K, Dent P, Mikkelsen R B & Schmidt-Ullrich R K, Epidermal growth factor receptor as a genetic therapy target for carcinoma cell radiosensitization, J Natl Cancer Inst, 93 (2001) 921.
144. Lammering G, Lin P S, Contessa J N, Hampton J L, Valerie K & Schmidt-Ullrich R K, Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells, Int J Radiat Oncol Biol Phys, 51 (2001) 775.
145. Lammering G, Valerie K, Lin P S, Mikkelsen R B, Contessa J N, Feden J P, Farnsworth J, Dent P & Schmidt-Ullrich R K, Radiosensitization of malignant glioma cells through overexpression of dominant-negative epidermal growth factor receptor, Clin Cancer Res, 7 (2001) 682.
146. Ross J S & Fletcher J A, The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy, Stem Cells, 16 (1998) 413.
147. Ochs J S, Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumors, Int J Radiat Oncol Biol Phys, 58 (2004) 941.
148. Shintani S, Kiyota A, Mihara M, Sumida T, Kayahara H, Nakashiro K & Hamakawa H, Enhancement of radiosensitivity in head and neck cancer cells by ZD1839 ('IRESSA'), a selective epidermal growth factor receptor tyrosine kinase inhibitor, Am J Clin Oncol, 26 (2003) e150.
149. Schiller J H, New directions for ZD1839 in the treatment of solid tumors, Semin Oncol, 30 (2003) 49.
150. Goldkorn T, Balaban N, Shannon M & Matsukuma K, EGF receptor phosphorylation is affected by ionizing radiation, Biochim Biophys Acta, 1358 (1997) 289.
151. Ciardiello F & Tortora G, A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor, Clin Cancer Res, 1 (2001) 2958.
152. Zhou H, Kim Y S, Peletier A, McCall W, Earp H S & Sartor C I, Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance, Int J Radiat Oncol Biol Phys, 58 (2004) 344.
153. Riesterer O, Tenzer A, Zingg D, Hofstetter B, Vuong V, Pruschy M & Bodis S, Novel radiosensitizers for locally advanced epithelial tumors: inhibition of the PI3K/Akt survival pathway in tumor cells and in tumor-associated endothelial cells as a novel treatment strategy?, Int J Radiat Oncol Biol Phys, 58 (2004) 361.
154. Mellinghoff I K, Tran C & Sawyers C L, Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts, Cancer Res, 62 (2002) 5254.
155. Bonner J A, Raisch K P, Trummell H Q, Robert F, Meredith R F, Spencer S A, Buchsbaum D J, Saleh M N, Stackhouse M A, LoBuglio A F, Peters G E, Carroll W R & Waksal H W, Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers, J Clin Oncol, 18 (2000) 47S.
156. Huang S M & Harari P M, Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results, Invest New Drugs, 17 (1999) 259.
157. Huang S M, Bock J M & Harari P M, Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck, Cancer Res, 59 (1999) 1935.
158. Bernhard E J, McKenna W G, Hamilton A D, Sebti S M, Qian Y, Wu J M & Muschel R J, Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes, Cancer Res, 58 (1998) 1754.
159. Alcock R A, Dey S, Chendil D, Inayat M S, Mohiuddin M, Hartman G, Chatfield L K, Gallicchio V S & Ahmed M M, Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2, Oncogene, 21 (2002) 7883.
160. Gokhale P C, McRae D, Monia B P, Bagg A, Rahman A, Dritschilo A & Kasid U, Antisense raf oligodeoxyribonucleotide is a radiosensitizer in vivo, Antisense Nucleic Acid Drug Dev, 9 (1999) 191.
161. Grunwald V & Hidalgo M, Developing inhibitors of the epidermal growth factor receptor for cancer treatment, J Natl Cancer Inst, 95 (2003) 851.
162. Gupta A K, Cerniglia G J, Mick R, Ahmed M S, Bakanauskas V J, Muschel R J & McKenna W G, Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002, Int J Radiat Oncol Biol Phys, 56 (2003) 846.
163. Ghosh P M, Malik S, Bedolla R & Kreisberg J I, Akt in prostate cancer: possible role in androgen-independence, Curr Drug Metab, 4 (2003) 487.
164. Chatterjee B, The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer, Mol Cell Biochem, 253 (2003) 89.
165. Maira S M, Galetic I, Brazil D P, Kaech S, Ingley E, Thelen M & Hemmings B A, Carboxyl-terminal modulator protein (CTMP), a negative regulator of PKB/Akt and v-Akt at the plasma membrane, Science, 294 (2001) 374.
166. Hill M M, Andjelkovic M, Brazil D P, Ferrari S, Fabbro D & Hemmings B A, Insulin-stimulated protein kinase B phosphorylation on Ser-473 is independent of its activity and occurs through a staurosporine-insensitive kinase, J Biol Chem, 276 (2001) 25643.
167. Stepczynska A, Lauber K, Engels I H, Janssen O, Kabelitz D, Wesselborg S & Schulze-Osthoff K, Staurosporine and conventional anticancer drugs induce overlapping, yet distinct pathways of apoptosis and caspase activation, Oncogene, 20 (2001) 1193.
168. Begemann M, Kashimawo S A, Heitjan D F, Schiff P B, Bruce J N & Weinstein I B, Treatment of human glioblastoma cells with the staurosporine derivative CGP 41251 inhibits CDC2 and CDK2 kinase activity and increases radiation sensitivity, Anticancer Res, 18 (1998) 2275.
169. Fabbro D, Ruetz S, Bodis S, Pruschy M, Csermak K, Man A, Campochiaro P, Wood J, O'Reilly T & Meyer T, PKC412 - a protein kinase inhibitor with a broad therapeutic potential, Anticancer Drug Des, 15 (2000) 17.
170. Begemann M, Kashimawo S A, Lunn R M, Delohery T, Choi Y J, Kim S, Heitjan D F, Santella R M, Schiff P B, Bruce J N & Weinstein I B, Growth inhibition induced by Ro 31-8220 and calphostin C in human glioblastoma cell lines is associated with apoptosis and inhibition of CDC2 kinase, Anticancer Res, 18 (1998) 3139.
171. Shao R G, Shimizu T & Pommier Y, 7-Hydroxystaurosporine (UCN-01) induces apoptosis in human colon carcinoma and leukemia cells independently of p53, Exp Cell Res, 234 (1997) 388.
172. Sato S, Fujita N & Tsuruo T, Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine), Oncogene, 21 (2002) 1727.
173. Persad S, Attwell S, Gray V, Delcommenne M, Troussard A, Sanghera J & Dedhar S, Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells, Proc Natl Acad Sci U S A, 97 (2000) 3207.
174. Yoganathan T N, Costello P, Chen X, Jabali M, Yan J, Leung D, Zhang Z, Yee A, Dedhar S & Sanghera J, Integrin-linked kinase (ILK): a "hot" therapeutic target, Biochem Pharmacol, 60 (2000) 1115.
175. Tan C, Costello P, Sanghera J, Dominguez D, Baulida J, de Herreros A G & Dedhar S, Inhibition of integrin linked kinase (ILK) suppresses
176. Martelli A M, Tazzari P L, Tabellini G, Bortul R, Billi A M, Manzoli L, Ruggeri A, Conte R & Cócco L, A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells, Leukemia, 17 (2003) 1794.
177. Gupta S, Stuffrein S, Plattner R, Tencati M, Gray C, Whang Y E & Stanbridge E J, Role of phosphoinositide 3-kinase in the aggressive tumor growth of HT1080 human fibrosarcoma cells, Mol Cell Biol, 21 (2001) 5846.
178. Gupta A K, McKenna W G, Weber C N, Feldman M D, Goldsmith J D, Mick R, Machtay M, Rosenthal D I, Bakanauskas V J, Cerniglia G J, Bernhard E J, Weber R S & Muschel R J, Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction, Clin Cancer Res, 8 (2002) 885.
179. Cataldi A, Zauli G, Di Pietro R, Castorina S & Rana R, Involvement of the pathway phosphatidylinositol-3-kinase/AKT-1 in the establishment of the survival response to ionizing radiation, Cell Signal, 13 (2001) 369.
180. Hsu A L, Ching T T, Wang D S, Song X, Rangnekar V M & Chen C S, The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2, J Biol Chem, 275 (2000) 11397.
181. Miyake H, Tolcher A & Cleave M E, Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model, Cancer Res, 59 (1999) 4030.
182. Chen S, Song C S, Lavrovsky Y, Bi B, Vellanoweth R, Chatterjee B & Roy A K, Catalytic cleavage of the androgen receptor messenger RNA and functional inhibition of androgen receptor activity by a hammerhead ribozyme, Mol Endocrinol, 12 (1998) 1558.
183. Wilce J A, Leedman P J & Wilce M C, RNA-binding proteins that target the androgen receptor mRNA, IUBMB Life, 54 (2002) 345.
184. Lee S J, Kim H S, Yu R, Lee K, Gardner T A, Jung C, Jeng M H, Yeung F, Cheng L & Kao C, Novel prostate-specific promoter derived from PSA and PSMA enhancers, Mol Ther, 6 (2002) 415.
185. Blackledge G R, Clinical progress with a new antiandrogen, Casodex (bicalutamide), Eur Urol, 29 Suppl 2 (1996) 96.
186. Song C S, Jung M H, Supakar P C, Chen S, Vellanoweth R L, Chatterjee B & Roy A K, Regulation of androgen action by receptor gene inhibition, Ann N Y Acad Sci, 761 (1995) 97.
187. Howell S J, Johnston S R & Howell A, The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer, Best Pract Res Clin Endocrinol Metab, 18 (2004) 47.
188. Magnusson C & Vaux D L, Signalling by CD95 and TNF receptors: not only life and death, Immunol Cell Biol, 77 (1999) 41.
189. Pena L A, Fuks Z & Kolesnick R, Stress-induced apoptosis and the sphingomyelin pathway, Biochem Pharmacol, 53 (1997) 615.
190. Wells G B, Dickson R C & Lester R L, Heat-induced elevation of ceramide in Saccharomyces cerevisiae via de novo synthesis, J Biol Chem, 273 (1998) 7235.
191. Samsel L, Zaidel G, Drumgoole H M, Jelovac D, Drachenberg C, Rhee J G, Brodie A M, Bielawska A & Smyth M J, The ceramide analog, B13, induces apoptosis in prostate cancer cell lines and inhibits tumor growth in prostate cancer xenografts, Prostate, 58 (2004) 382.
192. Davis R J, Signal transduction by the c-Jun N-terminal kinase, Biochem Soc Symp, 64 (1999) 1.
193. Chmura S J, Mauceri H J, Advani S, Heimann R, Beckett M A, Nodzenski E, Quintans J, Kufe D W & Weichselbaum R R, Decreasing the apoptotic threshold of tumor cells through protein kinase C inhibition and sphingomyelinase activation increases tumor killing by ionizing radiation, Cancer Res, 57 (1997) 4340.
194. Mathias S, Pena L A & Kolesnick R N, Signal transduction of stress via ceramide, Biochem J, 335 (Pt 3) (1998) 465.
195. Auer K L, Contessa J, Brenz-Verca S, Pirola L, Rusconi S, Cooper G, Abo A, Wymann M P, Davis R J, Birrer M & Dent P, The Ras/Rac1/Cdc42/SEK/JNK/c- Jun cascade is a key pathway by which agonists stimulate DNA synthesis in primary cultures of rat hepatocytes, Mol Biol Cell, 9 (1998) 561.
196. Potapova O, Haghighi A, Bost F, Liu C, Birrer M J, Gjerset R & Mercola D, The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin, J Biol Chem, 272 (1997) 14041.
197. Oktay M, Wary K K, Dans M, Birge R B & Giancotti F G, Integrin-mediated activation of focal adhesion kinase is required for signaling to Jun NH2-terminal kinase and progression through the G1 phase of the cell cycle, J Cell Biol, 145 (1999) 1461.
198. Wong G H, Kaspar R L, Zweiger G, Carlson C, Fong S E, Ehsani N & Vehar G, Strategies for manipulating apoptosis for cancer therapy with tumor necrosis factor and lymphotoxin, J Cell Biochem, 60 (1996) 56.
199. Weichselbaum R R, Kufe D W, Hellman S, Rasmussen H S, King C R, Fischer P H & Mauceri H J, Radiation-induced tumour necrosis factor-alpha expression: clinical application of transcriptional and physical targeting of gene therapy, Lancet Oncol, 3 (2002) 665.
200. Rieger J, Naumann U, Glaser T, Ashkenazi A & Weller M, APO2 ligand: a novel lethal weapon against malignant glioma?, FEBS Lett, 427 (1998) 124.
201. Ashkenazi A, Pai R C, Fong S, Leung S, Lawrence D A, Marsters S A, Blackie C, Chang L, McMurtrey A E, Hebert A, DeForge L, Koumenis I L, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z & Schwall R H, Safety and antitumor activity of recombinant soluble Apo2 ligand, J Clin Invest, 104 (1999) 155.
202. Walczak H, Miller R E, Ariail K, Gliniak B, Griffith T S, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin R G, Rauch C T, Schuh J C & Lynch D H, Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo, Nat Med, 5 (1999) 157.
203. Roth W, Isenmann S, Naumann U, Kugler S, Bahr M, Dichgans J, Ashkenazi A & Weller M, Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity, Biochem Biophys Res Commun, 265 (1999) 479.
204. Ahmed M M, Sells S F, Venkatasubbarao K, Fruitwala S M, Muthukkumar S, Harp C, Mohiuddin M & Rangnekar V M, Ionizing radiation-inducible apoptosis in the absence of p53 linked to transcription factor EGR-1, J Biol Chem, 272 (1997) 33056.
205. Ahmed M M, Regulation of radiation-induced apoptosis by early growth response-1 gene in solid tumors, Curr Cancer Drug Targets, 4 (2004) 43.
206. Morgan S E & Kastan M B, p53 and ATM: cell cycle, cell death, and cancer, Adv Cancer Res, 71 (1997) 1.
207. Giaccia A J & Kastan M B, The complexity of p53 modulation: emerging patterns from divergent signals, Genes Dev, 12 (1998) 2973.
208. Fan S, el-Deiry W S, Bae I, Freeman J, Jondle D, Bhatia K, Fornace A J, Jr. Magrath I, Kohn K W & O'Connor P M, p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents, Cancer Res, 54 (1994) 5824.
209. Chiarugi V, Magnelli L & Cinelli M, Role of p53 mutations in the radiosensitivity status of tumor cells, Tumori, 84 (1998) 517.
210. Lam V, McPherson J P, Salmena L, Lees J, Chu W, Sexsmith E, Hedley D W, Freedman M H, Reed J C, Malkin D & Goldenberg G J, p53 gene status and chemosensitivity of childhood acute lymphoblastic leukemia cells to adriamycin, Leuk Res, 23 (1999) 871.
211. Lai S L, Perng R P & Hwang J, p53 gene status modulates the chemosensitivity of non-small cell lung cancer cells, J Biomed Sci, 7 (2000) 64.
212. Su L N & Little J B, Transformation and radiosensitivity of human diploid skin fibroblasts transfected with SV40 T-antigen mutants defective in RB and P53 binding domains, Int J Radiat Biol, 62 (1992) 461.
213. Lee J M & Bernstein A, p53 mutations increase resistance to ionizing radiation, Proc Natl Acad Sci U S A, 90 (1993) 5742.
214. Haas-Kogan D A, Kogan S S, Yount G, Hsu J, Haas M, Deen D F & Israel M A, p53 function influences the effect of fractionated radiotherapy on glioblastoma tumors, Int J Radiat Oncol Biol Phys, 43 (1999) 399.
215. Ribeiro J C, Barnetson A R, Fisher R J, Mameghan H & Russell P J, Relationship between radiation response and p53 status in human bladder cancer cells, Int J Radiat Biol, 72 (1997) 11.
216. Tada M, Matsumoto R, Iggo R D, Onimaru R, Shirato H, Sawamura Y & Shinohe Y, Selective sensitivity to radiation of cerebral glioblastomas harboring p53 mutations, Cancer Res, 58 (1998) 1793.
217. Chen G & Lee E, The product of the ATM gene is a 370-kDa nuclear phosphoprotein, J Biol Chem, 271 (1996) 33693.
218. Jung M, Zhang Y, Lee S & Dritschilo A, Correction of radiation sensitivity in ataxia telangiectasia cells by a truncated I kappa B-alpha, Science, 268 (1995) 1619.
219. Baskaran R, Wood L D, Whitaker L L, Canman C E, Morgan S E, Xu Y, Barlow C, Baltimore D, Wynshaw-Boris A, Kastan M B & Wang J Y, Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation, Nature, 387 (1997) 516.
220. Khanna K K, Yan J, Watters D, Hobson K, Beamish H, Spring K, Shiloh Y, Gatti R A & Lavin M F, Defective signaling through the B cell antigen receptor in Epstein-Barr virus-transformed ataxia-telangiectasia cells, J Biol Chem, 272 (1997) 9489.
221. Arcinas M, Sizer K C & Boxer L M, Activation of c-myc expression by c-Abl is independent of both the DNA binding function of c-Abl and the c-myc EP site, J Biol Chem, 269 (1994) 21919.
222. Friedberg E. C. W G C a W S, DNA repair and mutagenesis, (ASM Press, Washington, DC) 1995, 662.
223. Siliciano J D, Canman C E, Taya Y, Sakaguchi K, Appella E & Kastan M B, DNA damage induces phosphorylation of the amino terminus of p53, Genes Dev, 11 (1997) 3471.
224. Khanna K K, Keating K E, Kozlov S, Scott S, Gatei M, Hobson K, Taya Y, Gabrielli B, Chan D, Lees-Miller S P & Lavin M F, ATM associates with and phosphorylates p53: mapping the region of interaction, Nat Genet, 20 (1998) 398.
225. Waterman M J, Stavridi E S, Waterman J L & Halazonetis T D, ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins, Nat Genet, 19 (1998) 175.
226. Canman C E, Wolff A C, Chen C Y, Fornace A J, Jr. & Kastan M B, The p53-dependent G1 cell cycle checkpoint pathway and ataxia-telangiectasia, Cancer Res, 54 (1994) 5054.
227. Kuerbitz S J, Plunkett B S, Walsh W V & Kastan M B, Wild-type p53 is a cell cycle checkpoint determinant following irradiation, Proc Natl Acad Sci U S A, 89 (1992) 7491.
228. Komarova E A & Gudkov A V, Could p53 be a target for therapeutic suppression?, Semin Cancer Biol, 8 (1998) 389.
229. Kruh J, Effects of sodium butyrate, a new pharmacological agent, on cells in culture, Mol Cell Biochem, 42 (1982) 65.
230. Phiel C J, Zhang F, Huang E Y, Guenther M G, Lazar M A & Klein P S, Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen, J Biol Chem, 276 (2001) 36734.
231. Suzuki T, Ando T, Tsuchiya K, Fukazawa N, Saito A, Mariko Y, Yamashita T & Nakanishi O, Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives, J Med Chem, 42 (1999) 3001.
232. Jung M, Brosch G, Kolle D, Scherf H, Gerhauser C & Loidl P, Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation, J Med Chem, 42 (1999) 4669.
233. Furumai R, Komatsu Y, Nishino N, Khochbin S, Yoshida M & Horinouchi S, Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin, Proc Natl Acad Sci U S A, 98 (2001) 87.
234. Richon V M, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind R A & Marks P A, A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases, Proc Natl Acad Sci U S A, 95 (1998) 3003.
235. Kijima M, Yoshida M, Sugita K, Horinouchi S & Beppu T, Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase, J Biol Chem, 268 (1993) 22429.
236. Han J W, Ahn S H, Park S H, Wang S Y, Bae G U, Seo D W, Kwon H K, Hong S, Lee H Y, Lee Y W & Lee H W, Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin, Cancer Res, 60 (2000) 6068.
237. Nakajima H, Kim Y B, Terano H, Yoshida M & Horinouchi S, FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor, Exp Cell Res, 241 (1998) 126.
238. Butler L M, Agus D B, Scher H I, Higgins B, Rose A, Cordon-Cardo C, Thaler H T, Rifkind R A, Marks P A & Richon V M, Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo, Cancer Res, 60 (2000) 5165.
239. Marks P A, Richon V M & Rifkind R A, Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells, J Natl Cancer Inst, 92 (2000) 1210.
240. Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, Suzuki T, Tsuruo T & Nakanishi O, A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors, Proc Natl Acad Sci U S A, 96 (1999) 4592.
241. Biade S, Stobbe C C, Boyd J T & Chapman J D, Chemical agents that promote chromatin compaction radiosensitize tumour cells, Int J Radiat Biol, 77 (2001) 1033.
242. Arundel C M, Glicksman A S & Leith J T, Enhancement of radiation injury in human colon tumor cells by the maturational agent sodium butyrate (NaB), Radiat Res, 104 (1985) 443.
243. Camphausen K, Burgan W, Cerra M, Oswald K A, Trepel J B, Lee M J & Tofilon P J, Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275, Cancer Res, 64 (2004) 316.
244. Gupta Seema, C-S C & Ahmed Mansoor M, Radiosensitization of prostate cancer cells (PC-3) by novel histone deacetylase inhibitors. 51st Annual Meeting of the Radiation Research Society, St. Louis, Missouri, 2004.
245. Darnell J E, Jr., Transcription factors as targets for cancer therapy, Nat Rev Cancer, 2 (2002) 740.
246. Schwartz S A, Hernandez A & Mark Evers B, The role of NF-kappaB/IkappaB proteins in cancer: implications for novel treatment strategies, Surg Oncol, 8 (1999) 143.
247. Yu H & Jove R, The STATs of cancer - new molecular targets come of age, Nat Rev Cancer, 4 (2004) 97.
248. Kurland J F, Kodym R, Story M D, Spurgers K B, McDonnell T J & Meyn R E, NF-kappaB1 (p50) homodimers contribute to transcription of the bcl-2 oncogene, J Biol Chem, 276 (2001) 45380.
249. Russo S M, Tepper J E, Baldwin A S Jr., Liu R, Adams J, Elliott P & Cusack J C Jr., Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB, Int J Radiat Oncol Biol Phys, 50 (2001) 183.
250. Pajonk F, Himmelsbach J, Riess K, Sommer A & McBride W H, The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells, Cancer Res, 62 (2002) 5230.
251. Chendil D, Das A, Dey S, Mohiuddin M & Ahmed M M, Par-4, a pro-apoptotic gene, inhibits radiation-induced NF kappa B activity and Bcl-2 expression leading to induction of radiosensitivity in human prostate cancer cells PC-3, Cancer Biol Ther, 1 (2002) 152.
252. Niu G, Heller R, Catlett-Falcone R, Coppola D, Jaroszeski M, Dalton W, Jove R & Yu H, Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo, Cancer Res, 59 (1999) 5059.
253. Bowman T, Broome M A, Sinibaldi D, Wharton W, Pledger W J, Sedivy J M, Irby R, Yeatman T, Courtneidge S A & Jove R, Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis, Proc Natl Acad Sci U S A, 98 (2001) 7319.
254. Turkson J, Ryan D, Kim J S, Zhang Y, Chen Z, Haura E, Laudano A, Sebti S, Hamilton A D & Jove R, Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation, J Biol Chem, 276 (2001) 45443.
255. Catlett-Falcone R, Landowski T H, Oshiro M M, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna J L, Nunez G, Dalton W S & Jove R, Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells, Immunity, 10 (1999) 105.
256. Garcia R, Bowman T L, Niu G, Yu H, Minton S, Muro-Cacho C A, Cox C E, Falcone R, Fairclough R, Parsons S, Laudano A, Gazit A, Levítzki A, Kraker A & Jove R, Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells, Oncogene, 20 (2001) 2499.
257. Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A, Chang A, Kraker A, Jove R & Yu H, Roles of activated Src and Stat3 signaling in melanoma tumor cell growth, Oncogene, 21 (2002) 7001.
258. Huang M, Dorsey J F, Epling-Burnette P K, Nimmanapalli R, Landowski T H, Mora L B, Niu G, Sinibaldi D, Bai F, Kraker A, Yu H, Moscinski L, Wei S, Djeu J, Dalton W S, Bhalla K, Loughran T P, Wu J & Jove R, Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells, Oncogene, 21 (2002) 8804.
259. Levis M, Allebach J, Tse K F, Zheng R, Baldwin B R, Smith B D, Jones-Bolin S, Ruggeri B, Dionne C & Small D, A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo, Blood, 99 (2002) 3885.
260. Grandis J R, Drenning S D, Chakraborty A, Zhou M Y, Zeng Q, Pitt A S & Tweardy D J, Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth In vitro, J Clin Invest, 102 (1998) 1385.
261. Frank D A, StAT signaling in cancer: insights into pathogenesis and treatment strategies, Cancer Treat Res, 115 (2003) 267.
262. Turkson J & Jove R, STAT proteins: novel molecular targets for cancer drug discovery, Oncogene, 19 (2000) 6613.
263. Sillaber C, Gesbert F, Frank D A, Sattler M & Griffin J D, STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells, Blood, 95 (2000) 2118.
264. Konnikova L, Kotecki M, Kruger M M & Cochran B H, Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells, BMC Cancer, 3 (2003) 23.
265. Leong P L, Andrews G A, Johnson D E, Dyer K F, Xi S, Mai J C, Robbins P D, Gadiparthi S, Burke N A, Watkins S F & Grandis J R, Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth, Proc Natl Acad Sci U S A, 100 (2003) 4138.
266. Lu B, Mu Y, Cao C, Zeng F, Schneider S, Tan J, Price J, Chen J, Freeman M & Hallahan D E, Survivin as a therapeutic target for radiation sensitization in lung cancer, Cancer Res, 64 (2004) 2840.
267. Pennati M, Binda M, Colella G, Folini M, Citti L, Villa R, Daidone M G & Zaffaroni N, Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expression, J Invest Dermatol, 120 (2003) 648.
268. Asanuma K, Kobayashi D, Furuya D, Tsuji N, Yagihashi A & Watanabe N, A role for survivin in radioresistance of pancreatic cancer cells, Jpn J Cancer Res, 93 (2002) 1057.
269. Rohayem J, Diestelkoetter P, Weigle B, Oehmichen A, Schmitz M, Mehlhorn J, Conrad K & Rieber E P, Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients, Cancer Res, 60 (2000) 1815.
270. Andersen M H, Pedersen L O, Capeller B, Brocker E B, Becker J C & thor Straten P, Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients, Cancer Res, 61 (2001) 5964.
271. Schmitz M, Diestelkoetter P, Weigle B, Schmachtenberg F, Stevanovic S, Ockert D, Rammensee H G & Rieber E P, Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides, Cancer Res, 60 (2000) 4845.
272. Jung M & Dritschilo A, NF-kappa B signaling pathway as a target for human tumor radiosensitization, Semin Radiat Oncol, 11 (2001) 346.
273. Russell J S, Raju U, Gumin G J, Lang F F, Wilson D R, Huet T & Tofilon P J, Inhibition of radiation-induced nuclear factor-kappaB activation by an anti-Ras single-chain antibody fragment: lack of involvement in radiosensitization, Cancer Res, 62 (2002) 2318.
274. Bhat-Nakshatri P, Sweeney C J & Nakshatri H, Identification of signal transduction pathways involved in constitutive NF-kappaB activation in breast cancer cells, Oncogene, 21 (2002) 2066.
275. Troppmair J, Hartkamp J & Rapp U R, Activation of NF-kappa B by oncogenic Raf in HEK 293 cells occurs through autocrine recruitment of the stress kinase cascade, Oncogene, 17 (1998) 685.
276. Barradas M, Monjas A, Diaz-Meco M T, Serrano M & Moscat J, The downregulation of the pro-apoptotic protein Par-4 is critical for Ras-induced survival and tumor progression, Embo J, 18 (1999) 6362.
277. Qiu S G, Krishnan S, el-Guendy N & Rangnekar V M, Negative regulation of Par-4 by oncogenic Ras is essential for cellular transformation, Oncogene, 18 (1999) 7115.
278. Wang Y M, Seibenhener M L, Vandenplas M L & Wooten M W, Atypical PKC zeta is activated by ceramide, resulting in coactivation of NF-kappaB/JNK kinase and cell survival, J Neurosci Res, 55 (1999) 293.
279. Chakraborty M, Qiu S G, Vasudevan K M & Rangnekar V M, Par-4 drives trafficking and activation of Fas and Fas1 to induce prostate cancer cell apoptosis and tumor regression, Cancer Res, 61 (2001) 7255.
280. Dent P, Yacoub A, Contessa J, Caron R, Amorino G, Valerie K, Hagan M P, Grant S & Schmidt-Ullrich R, Stress and radiation-induced activation of multiple intracellular signaling pathways. Radiat Res, 159 (2003) 283.
281. Teitz T, Wei T, Valentine M B, Vanin E F, Grenet J, Valentine V A, Behm F G, Look A T, Lahti J M & Kidd V J, Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN, Nat Med, 6 (2000) 529.
282. Kurland J F & Meyn R E, Protease inhibitors restore radiation-induced apoptosis to Bcl-2-expressing lymphoma cells, Int J Cancer, 96 (2001) 327.
283. Wacheck V, Selzer E, Gunsberg P, Lucas T, Meyer H, Thallinger C, Monia B P & Jansen B, Bcl-x(L) antisense oligonucleotides radiosensitise colon cancer cells, Br J Cancer, 89 (2003) 1352.
284. Manion M K & Hockenbery D M, Targeting BCL-2-related proteins in cancer therapy, Cancer Biol Ther, 2 (2003) S105.
285. Scott S L, Higdon R, Beckett L, Shi X B, deVere White R W, Earle J D & Gumerlock P H, BCL2 antisense reduces prostate cancer cell survival following irradiation, Cancer Biother Radiopharm, 17 (2002) 647.
286. Uchida T, Gao J P, Wang C, Satoh T, Itoh I, Muramoto M, Hyodo T, Irie A, Akahoshi T, Jiang S X, Kameya T & Baba S, Antitumor effect of bcl-2 antisense phosphorothioate oligodeoxynucleotides on human renal-cell carcinoma cells in vitro and in mice, Mol Urol, 5 (2001) 71.
287. Hong J H, Lee E, Hong J, Shin Y J & Ahn H, Antisense Bcl2 oligonucleotide in cisplatin-resistant bladder cancer cell lines, BJU Int, 90 (2002) 113.
288. Mauceri H J, Hanna N N, Wayne J D, Hallahan D E, Hellman S & Weichselbaum R R, Tumor necrosis factor alpha (TNF-alpha) gene therapy targeted by ionizing radiation selectively damages tumor vasculature, Cancer Res, 56 (1996) 4311.
289. Hallahan D E, Vokes E E, Rubin S J, O'Brien S, Samuels B, Vijaykumar S, Kufe D W, Phillips R & Weichselbaum R R, Phase I Dose-Escalation Study of Tumor Necrosis Factor-alpha and Concomitant Radiation Therapy, Cancer J Sci Am, 1 (1995) 204.
290. Seung L P, Mauceri H J, Beckett M A, Hallahan D E, Hellman S & Weichselbaum R R, Genetic radiotherapy overcomes tumor resistance to cytotoxic agents, Cancer Res, 55 (1995) 5561.
291. Mauceri H J, Seung L P, Grdina W L, Swedberg K A & Weichselbaum R R, Increased injection number enhances adenoviral genetic radiotherapy, Radiat Oncol Investig, 5 (1997) 220.
292. Staba M J, Mauceri H J, Kufe D W, Hallahan D E & Weichselbaum R R, Adenoviral TNF-alpha gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft, Gene Ther, 5 (1998) 293.
293. Weichselbaum R R, Kufe D W, Advani S J & Roizman B, Molecular targeting of gene therapy and radiotherapy, Acta Oncol, 40 (2001) 735.
294. Rasmussen H, Rasmussen C, Lempicki M, Durham R, Brough D, King C R & Weichselbaum R, TNFerade Biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene, Cancer Gene Ther, 9 (2002) 951.
295. Sharma A, Mani S, Hanna N, Guha C, Vikram B, Weichselbaum R R, Sparano J, Sood B, Lee D, Regine W, Muhodin M, Valentino J, Herman J, Desimone P, Arnold S, Carrico J, Rockich A K, Warner-Carpenter J & Barton-Baxter M, Clinical protocol. An open-label, phase I, dose-escalation study of tumor necrosis factor-alpha (TNFerade Biologic) gene transfer with radiation therapy for locally advanced, recurrent, or metastatic solid tumors, Hum Gene Ther, 12 (2001) 1109.
296. Joiner M C, Induced radioresistance: an overview and historical perspective, Int J Radiat Biol, 65 (1994) 79.
297. Lambin P, Marples B, Fertil B, Malaise E P & Joiner M C, Hypersensitivity of a human tumour cell line to very low radiation doses, Int J Radiat Biol, 63 (1993) 639.
298. Marples B, Lambin P, Skov K A & Joiner M C, Low dose hyper-radiosensitivity and increased radioresistance in mammalian cells, Int J Radiat Biol, 71 (1997) 721.
299. Wouters B G & Skarsgard L D, The response of a human tumor cell line to low radiation doses: evidence of enhanced sensitivity, Radiat Res, 138 (1994) S76.
300. Joiner M C, Marples B, Lambin P, Short S C & Turesson I, Low-dose hypersensitivity: current status and possible mechanisms, Int J Radiat Oncol Biol Phys, 49 (2001) 379.
301. Joiner M C & Johns H, Renal damage in the mouse: the response to very small doses per fraction, Radiat Res, 114 (1988) 385.
302. Chendil D, Oakes R, Alcock R A, Patel N, Mayhew C, Mohiuddin M, Gallicchio V S & Ahmed M M, Low dose fractionated radiation enhances the radiosensitization effect of paclitaxel in colorectal tumor cells with mutant p53, Cancer, 89 (2000) 1893.
303. Short S C, Mitchell S A, Boulton P, Woodcock M & Joiner M C, The response of human glioma cell lines to low-dose radiation exposure, Int J Radiat Biol, 75 (1999) 1341.
304. Marples B, Wouters B G, Collis S J, Chalmers A J & Joiner M C, Low-dose hyper-radiosensitivity: a consequence of ineffective cell cycle arrest of radiation-damaged G2-phase cells, Radiat Res, 161 (2004) 247.
305. Dey S, Spring P M, Arnold S, Valentino J, Chendil D, Regine W F, Mohiuddin M & Ahmed M M, Low-dose fractionated radiation potentiates the effects of Paclitaxel in wild-type and mutant p53 head and neck tumor cell lines, Clin Cancer Res, 9 (2003) 1557.
306. Short S C, Kelly J, Mayes C R, Woodcock M & Joiner M C, Low-dose hypersensitivity after fractionated low-dose irradiation in vitro, Int J Radiat Biol, 77 (2001) 655.
307. Dubey A K, Recht A, Come S, Shulman L & Harris J, Why and how to combine chemotherapy and radiation therapy in breast cancer patients, Recent Results Cancer Res, 152 (1998) 247.
308. Krause M, Hessel F, Wohlfarth J, Zips D, Hoinkis C, Foest H, Petersen C, Short S C, Joiner M C & Baumann M, Ultrafractionation in A7 human malignant glioma in nude mice, Int J Radiat Biol, 79 (2003) 377.
309. Beauchesne P D, Bertrand S, Branche R, Linke S P, Revel R, Dore J F & Pedeux R M, Human malignant glioma cell lines are sensitive to low radiation doses, Int J Cancer, 105 (2003) 33.
310. Spring P M, Arnold S M, Shajahan S, Brown B, Dey S, Lele S M, Valentino J, Jones R, Mohiuddin M & Ahmed M M, Low Dose Fractionated Radiation Potentiates the Effects of Taxotere in Nude Mice Xenografts of Squamous Cell Carcinoma of Head and Neck, Cell Cycle, 3 (2004) 479.
311. Gupta Seema, Paul Spring S M A, Mohiuddin Mohammed & Ahmed Mansoor M, Low-dose fractionated radiation potentiates the effect of cisplatin independent of the hyperradiation sensitivity phenomenon in human lung cancer cell lines. 95th Annual Meeting of American Association for Cancer Research, Orlando, Florida, 2004.
312. Kuo M T, Liu Z, Wei Y, Lin-Lee Y C, Tatebe S, Mills G B & Unate H, Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling, Oncogene, 21 (2002) 1945.
313. Mothersill C & Seymour C, Radiation-induced bystander effects: past history and future directions, Radiat Res, 155 (2001) 759.
314. Mothersill C & Seymour C, Medium from irradiated human epithelial cells but not human fibroblasts reduces the clonogenic survival of unirradiated cells, Int J Radiat Biol, 71 (1997) 421.
315. Mothersill C & Seymour C B, Cell-cell contact during gamma irradiation is not required to induce a bystander effect in normal human keratinocytes: evidence for release during irradiation of a signal controlling survival into the medium, Radiat Res, 149 (1998) 256.
316. Ballarini F & Ottolenghi A, Low-dose radiation action: possible implications of bystander effects and adaptive response, J Radiol Prot, 22 (2002) A39.
317. Lorimore S A, Kadhim M A, Pocock D A, Papworth D, Stevens D L, Goodhead D T & Wright E G, Chromosomal instability in the descendants of unirradiated surviving cells after alpha-particle irradiation, Proc Natl Acad Sci U S A, 95 (1998) 5730.
318. Wu L J, Randers-Pehrson G, Xu A, Waldren C A, Geard C R, Yu Z & Hei T K, Targeted cytoplasmic irradiation with alpha particles induces mutations in mammalian cells, Proc Natl Acad Sci U S A, 96 (1999) 4959.
319. Seymour C B & Mothersill C, Delayed expression of lethal mutations and genomic instability in the progeny of human epithelial cells that survived in a bystander-killing environment, Radiat Oncol Investig, 5 (1997) 106.
320. Lyng F M, Seymour C B & Mothersill C, Production of a signal by irradiated cells which leads to a response in unirradiated cells characteristic of initiation of apoptosis, Br J Cancer, 83 (2000) 1223.
321. Mothersill C, Rea D, Wright E G, Lorimore S A, Murphy D, Seymour C B & O'Malley K, Individual variation in the production of a 'bystander signal' following irradiation of primary cultures of normal human urothelium, Carcinogenesis, 22 (2001) 1465.
322. Azzam E I, de Toledo S M, Gooding T & Little J B, Intercellular communication is involved in the bystander regulation of gene expression in human cells exposed to very low fluences of alpha particles, Radiat Res, 150 (1998) 497.
323. Azzam E I, de Toledo S M, Waker A J & Little J B, High and low fluences of alpha-particles induce a G1 checkpoint in human diploid fibroblasts, Cancer Res, 60 (2000) 2623.
324. Mothersill C, Stamato T D, Perez M L, Cummins R, Mooney R & Seymour C B, Involvement of energy metabolism in the production of 'bystander effects' by radiation, Br J Cancer, 82 (2000) 1740.
325. Iyer R, Lehnert B E & Svensson R, Factors underlying the cell growth-related bystander responses to alpha particles, Cancer Res, 60 (2000) 1290.
326. Zhou H, Randers-Pehrson G, Waldren C A, Vannais D, Hall E J & Hei T K, Induction of a bystander mutagenic effect of alpha particles in mammalian cells, Proc Natl Acad Sci USA, 97 (2000) 2099.
327. Prise K M, Belyakov O V, Folkard M & Michael B D, Studies of bystander effects in human fibroblasts using a charged particle microbeam, Int J Radiat Biol, 74 (1998) 793.
328. Belyakov O V, Malcolmson A M, Folkard M, Prise K M & Michael B D, Direct evidence for a bystander effect of ionizing radiation in primary human fibroblasts, Br J Cancer, 84 (2001) 674.
329. Nuan Cui N D, Mohammed Mohiuddin & Mansoor M Ahmed, Role of EGR-1 function in high dose radiation-induced bystander effect. 95th Annual Meeting of American association for Cancer Research, Orlando, Florida, USA, 2004.
330. Mohiuddin M, Fujita M, Regine W F, Megooni A S, Ibbott G S & Ahmed M M, High-dose spatially-fractionated radiation (GRID): a new paradigm in the management of advanced cancers, Int J Radiat Oncol Biol Phys, 45 (1999) 721.
331. Sathishkumar S, Dey S, Meigooni A S, Regine W F, Kudrimoti M S, Ahmed M M & Mohiuddin M, The impact of TNF-alpha induction on therapeutic efficacy following high dose spatially fractionated (GRID) radiation, Technol Cancer Res Treat, 1 (2002) 141.
332. Sabapathi Sathishkumar B B, Krassimira Rozenova Nathalia V. Giltiay, Mahesh Kudrimoti, Mohammed Mohiuddin, Mansoor M Ahmed & Mariana Nikolova-Karakashian, High dose spatially fractionated (GRID) radiation elevates sphingomyelinase (SMase) activity and ceramide levels in serum: implication for radiation-induced endothelial apoptosis. 51st Annual Meeting of Radiation Research Society, held at Orlando, Florida, USA, (2004).